LRI Board Member Co-authors Paper on How Investigational Drug May Work in Lupus

The Wall Street Journal reported on a paper just published in the prestigious journal Blood described a mechanism by which epratuzumab affects B cells involved in lupus. Epratuzumab is a humanized anti-CD22 antibody currently in Phase III trials conducted by UCB as a potential treatment for lupus. We at the Lupus Research Institute are particularly proud because our Board member Dr. Daniel J. Wallace of Cedars-Sinai Medical Center of UCLA co-authored this important paper and is integrally involved in evaluating the safety and efficacy of epratuzumab in clinical trials.